Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
55 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Fatigue - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Fatigue - Pipeline Review, H2 2016', provides an overview of the Fatigue pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fatigue, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fatigue and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Fatigue - The report reviews pipeline therapeutics for Fatigue by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Fatigue therapeutics and enlists all their major and minor projects - The report assesses Fatigue therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Fatigue Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Fatigue - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Fatigue pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Fatigue Overview 6 Therapeutics Development 7 Pipeline Products for Fatigue - Overview 7 Fatigue - Therapeutics under Development by Companies 8 Fatigue - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Fatigue - Products under Development by Companies 12 Fatigue - Companies Involved in Therapeutics Development 13 BioLite, Inc. 13 Biovista Inc. 14 Grifols, S.A. 15 Hemispherx Biopharma, Inc. 16 MultiCell Technologies, Inc. 17 Fatigue - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Combination Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 (lofepramine hydrochloride + phenylalanine) - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 alpha-1 proteinase inhibitor (human) - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 BLI-1402 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Recombinant A1PI - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 rintatolimod - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Small Molecule for Chronic Fatigue Syndrome and Myalgic Encephalomyelitis - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Fatigue - Dormant Projects 43 Fatigue - Product Development Milestones 44 Featured News & Press Releases 44 Jun 07, 2016: Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, "Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)" in Expert Review of Clinical Pharmacology 44 Mar 10, 2016: Hemispherx Biopharma Reviews Ampligen Data with National Institute of Neurological Disorders and Stroke 45 Sep 21, 2015: Hemispherx Biopharma Research Team Identifies Characteristics of Chronic Fatigue Syndrome Patients Potentially Predictive of Improved Response to Ampligen 45 Sep 17, 2015: Hemispherx Biopharma Announces Patient Assistance Program for Chronic Fatigue Syndrome Open Label Study 46 Sep 15, 2015: Hemispherx Biopharma Reports Low NK Cell Activity in Chronic Fatigue Syndrome and Relationship to Disease Symptoms 47 Aug 10, 2015: Hemispherx Enters into an Agreement with myTomorrows for an Early Access Program for Rintatolimod in Europe 47 Jun 25, 2015: Hemispherx Receives the European Patent Office Examining Division's Notice of Intention to Grant the New Composition of Matter Patent Covering Ampligen Formulations 48 May 27, 2014: Hemispherx Receives New U.S. Composition of Matter Patent Covering Ampligen Formulations 49 May 21, 2014: Hemispherx and GP Pharm Agree to Establish a Manufacturing Operation in Argentina to Serve Latin America Markets and Ancillary Markets 49 Mar 24, 2014: Hemispherx Biopharma Presented Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference 50 Mar 19, 2014: Hemispherx Biopharma, Inc. to Present Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference 51 Mar 10, 2014: Hemispherx Biopharma Announces Plans to File for Regulatory Approval of Ampligen to Treat Chronic Fatigue Syndrome in Three Additional Latin America Countries 51 Feb 04, 2013: Hemispherx Biopharma Fails To Win FDA Approval For Its Chronic Fatigue Drug Ampligen 51 Dec 21, 2012: Hemispherx Biopharma Announces Outcome Of FDA Meeting On Ampligen 52 Oct 22, 2012: Hemispherx Biopharma Announces FDA Confirms Advisory Committee Meeting On December 20, 2012 53 Appendix 54 Methodology 54 Coverage 54 Secondary Research 54 Primary Research 54 Expert Panel Validation 54 Contact Us 54 Disclaimer 55
List of Tables
Number of Products under Development for Fatigue, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Late Stage Development, H2 2016 9 Comparative Analysis by Clinical Stage Development, H2 2016 10 Comparative Analysis by Early Stage Development, H2 2016 11 Products under Development by Companies, H2 2016 12 Fatigue - Pipeline by BioLite, Inc., H2 2016 13 Fatigue - Pipeline by Biovista Inc., H2 2016 14 Fatigue - Pipeline by Grifols, S.A., H2 2016 15 Fatigue - Pipeline by Hemispherx Biopharma, Inc., H2 2016 16 Fatigue - Pipeline by MultiCell Technologies, Inc., H2 2016 17 Assessment by Monotherapy Products, H2 2016 18 Assessment by Combination Products, H2 2016 19 Number of Products by Stage and Target, H2 2016 21 Number of Products by Stage and Mechanism of Action, H2 2016 23 Number of Products by Stage and Route of Administration, H2 2016 25 Number of Products by Stage and Molecule Type, H2 2016 27 Fatigue - Dormant Projects, H2 2016 43
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
